NASDAQ: SYBXSynlogic Inc Stock
$1.91+0.07 (+3.8%)
Updated Apr 23, 2024
SYBX Price
$1.91
Fair Value Price
N/A
Market Cap
$22.25M
52 Week Low
$1.55
52 Week High
$10.20
P/E
-0.22x
P/B
0.52x
P/S
7.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.37M
Earnings
-$57.28M
Gross Margin
100%
Operating Margin
-1,698.81%
Profit Margin
-1,699.3%
Debt to Equity
0.77
Operating Cash Flow
-$52M
Beta
1.2
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SYBX Overview
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SYBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SYBX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SYBX is good value based on its book value relative to its share price (0.52x), compared to the US Biotechnology industry average (5.93x)
P/B vs Industry Valuation
SYBX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SYBX due diligence checks available for Premium users.
Be the first to know about important SYBX news, forecast changes, insider trades & much more!
SYBX News
Valuation
SYBX fair value
Fair Value of SYBX stock based on Discounted Cash Flow (DCF)
Price
$1.91
Fair Value
$3.55
Undervalued by
46.19%
SYBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SYBX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
16.46x
Market
41.92x
SYBX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.52x
Industry
5.93x
SYBX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SYBX's financial health
Profit margin
Revenue
$2.8M
Net Income
-$14.5M
Profit Margin
-524.9%
SYBX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SYBX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$75.6M
Liabilities
$32.9M
Debt to equity
0.77
SYBX's short-term assets ($49.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SYBX's short-term assets ($49.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SYBX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SYBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.5M
Investing
-$14.6M
Financing
$19.6M
SYBX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SYBX vs Biotech Stocks
Synlogic Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.